Pfizer (NYSE:PFE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Pfizer (NYSE:PFE) from a hold rating to a buy rating in a research report report published on Sunday morning,Wall Street Zen reports.

Other research analysts also recently issued reports about the company. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research report on Monday, July 6th. JPMorgan Chase & Co. dropped their price target on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Wednesday, July 8th. Royal Bank Of Canada raised Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective for the company in a report on Tuesday, June 9th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Finally, BMO Capital Markets decreased their price objective on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average target price of $28.39.

Pfizer Stock Performance

PFE opened at $27.52 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The company has a market cap of $156.88 billion, a PE ratio of 36.22, a price-to-earnings-growth ratio of 1.86 and a beta of 0.34. The stock has a 50-day moving average of $26.50 and a 200-day moving average of $26.37. Pfizer has a 52-week low of $23.58 and a 52-week high of $29.21.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company’s revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts forecast that Pfizer will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th were paid a $0.43 dividend. The ex-dividend date was Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. Pfizer’s dividend payout ratio (DPR) is 226.32%.

Institutional Investors Weigh In On Pfizer

A number of hedge funds have recently added to or reduced their stakes in PFE. Handelsbanken Fonder AB increased its position in shares of Pfizer by 10.4% in the second quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock worth $59,295,000 after acquiring an additional 232,528 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Pfizer by 15.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock valued at $132,365,000 after acquiring an additional 745,213 shares in the last quarter. Leuthold Group LLC purchased a new stake in Pfizer during the 2nd quarter worth $4,887,000. North Dakota State Investment Board acquired a new stake in Pfizer in the 4th quarter valued at $5,348,000. Finally, Park National Corp OH raised its position in Pfizer by 332.1% in the second quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock valued at $5,829,000 after purchasing an additional 186,053 shares during the period. Institutional investors own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer is included among prostate-cancer drug companies to watch, highlighting its established oncology products and the potential for clinical, regulatory and commercial catalysts. Success in oncology could help offset pressure from older products. 4 Prostate Cancer Drug Stocks to Watch During Awareness Month
• Positive Sentiment: Analysts point to Pfizer’s newer products, acquisitions and pipeline as possible growth drivers beginning around 2029, offering a longer-term path beyond the current COVID and patent-related declines. Can Pfizer Overcome Its COVID and Patent Cliff Headwinds?

Pfizer Company Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its portfolio addresses a range of therapeutic areas, including oncology, inflammation and immunology, internal medicine, hospital care, rare diseases and infectious diseases. The company serves patients and healthcare providers in markets worldwide.

Pfizer’s products include the Comirnaty COVID-19 vaccine, the Prevnar family of pneumococcal vaccines, and medicines such as Eliquis, Ibrance, Vyndaqel and Zavzaret.